EMBC - NASDAQ
Embecta Corp.
$3.32
-2.8%Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
At a Glance
Live Snapshotembc
Accounts Receivables
Last Annual Value
145.60M
3-Year CAGR
84%
5-Year CAGR
4%
10-Year CAGR
1%
Embecta Corp. Competitors Analysis of Accounts Receivables
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Embecta Corp. NASDAQ:EMBC | 145.60M | 101.1% | -0.7% | N/A | |
 Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 25.50M | -22.4% | -26.3% | N/A | |
 CareDx, Inc NASDAQ:CDNA | 42.63M | -5.8% | -6.5% | 31.4% | |
 Prime Medicine, Inc. NASDAQ:PRME | 0.00 | N/A | N/A | N/A | |
 Personalis, Inc. NASDAQ:PSNL | 16.20M | -3.0% | -2.6% | N/A | |
 Aquestive Therapeutics, Inc. NASDAQ:AQST | 8.01M | 13.0% | -2.4% | -2.8% | |
 SIGA Technologies, Inc. NASDAQ:SIGA | 3.26M | -46.3% | -47.7% | 0.3% | |
 Evolent Health, Inc. NYSE:EVH | 323.40M | -10.2% | 19.9% | 23.1% | |
 Emergent BioSolutions Inc. NYSE:EBS | 84.20M | -15.5% | -21.3% | -4.9% | |
 Myriad Genetics, Inc. NASDAQ:MYGN | 115.30M | 0.3% | 4.8% | N/A | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 0.00 | N/A | N/A | N/A |
Embecta Corp. Fair Value Envelope
Related Guides
Continue your EMBC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.